Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

10.65 UNCHANGED

Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

April 17, 2023

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

April 06, 2023

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

April 05, 2023

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Expert Ratings for Enanta Pharma ↗

March 22, 2023

Via Benzinga

Enanta Pharmaceuticals's Earnings: A Preview ↗

February 06, 2023

Via Benzinga

Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research

March 14, 2023

From Enanta Pharmaceuticals, Inc.

Via Business Wire

10 Companies That Had Tons of Money in SVB When It Collapsed ↗

March 13, 2023

Silicon Valley Bank is gone but its clients are still here. Many prominent companies, and not just startups, had money in SVB.

Via InvestorPlace

March 08, 2023

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Earnings Outlook For Enanta Pharmaceuticals ↗

November 18, 2022

Via Benzinga

Recap: Enanta Pharmaceuticals Q3 Earnings ↗

August 08, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q3 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 07, 2023

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET

February 07, 2023

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

February 07, 2023

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022

January 31, 2023

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference

January 06, 2023

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in Two Investor Conferences in November

November 22, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

November 21, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For November 21, 2022 ↗

November 21, 2022

Companies Reporting Before The Bell • Zepp Health (NYSE:ZEPP) is expected to report quarterly earnings at $0.54 per share on revenue of $186.58 million.

Via Benzinga

Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022

November 14, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

November 09, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022

October 19, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

October 17, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

October 03, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium

September 29, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium

September 22, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022

September 07, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in Two Investor Conferences in September

September 01, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

August 08, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

August 08, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.